Autoantibodies associated with rheumatic diseases

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 3, 2001, Pages 189-208

  Griesmacher, A ^a   Peichl, P ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Antibody; Autoantibodies; Autoimmune disease

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CELL ANTIBODY; MITOCHONDRION ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR;

ALGORITHM; ANIMAL CELL; ANIMAL TISSUE; ASSAY; AUTOIMMUNE DISEASE; CIRCULATION; CONTROLLED STUDY; CORRELATION FUNCTION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; HUMAN CELL; LABORATORY DIAGNOSIS; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; PARAMETER; PREDICTION; PRIORITY JOURNAL; RAT; REVIEW; RHEUMATIC DISEASE; SCREENING;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RHEUMATIC DISEASES; RHEUMATOID FACTOR;

ANIMALIA;

EID: 0035041173     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.031     Document Type: Review

References (194)

1. Pathogenic significance and diagnostic value of lupus autoantibodies
2. Mechanism of disordered immune regulation
3. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis
4. Presentation of two bone marrow elements: The 'tart' cell and 'LE' cell
5. revised criteria for the classification of rheumatoid arthritis
6. Rheumatoid factor
7. The rheumatoid factor: An analysis of clinical utility
8. Onset, early stages, and prognosis of rheumatoid arthritis: A clinical study of 100 patients with 11-year follow up
9. On the distribution of rheumatoid factor among the immunoglobulins
10. IgA rheumatoid factor in the serum and saliva of patients with rheumatoid arthritis and Sjögren's syndrome
11. IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgF RF detected by ELISA in rheumatoid arthritis
12. Measurement of rheumatoid factors by an enzyme linked immunosorbent assay (ELISA) and comparison with other methods
13. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis
14. Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor
15. Prospective study of early rheumatoid arthritis. II. Association of the rheumatoid factor isotypes with disease activity
16. Relation between bone erosions and rheumatoid factor isotypes
17. Clinical significance of IgA rheumatoid factor subclasses in rheumatoid arthritis
18. IgA isotype rheumatoid factor in rheumatopid arthritis: Clinical implications
19. Raised IgA rheumatoid factor but not IgM RF or IgG RF is associated with extraarticular manifestations in rheumatoid arthritis
20. Relationship of rheumatoid factor isotype levels with joint lesions detected by magnetic resonance imaging in early rheumatoid arthritis
21. Gamma globulin complexes in rheumatoid arthritis and certain other conditions
22. Radio-immunoassay of IgG and IgM rheumatoid factors reacting with human IgG
23. IgG, IgM and IgA rheumatoid factor in healthy adults and rheumatoid patients by an indirect immunofluorescence method
24. Measurement of rheumatoid factors by an enzyme linked immunosorbent assay (ELISA) and comparison with other methods
25. IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis
26. IgG rheumatoid factor. Relationship to seropositive rheumatoid arthritis and absence in seronegative disorders
27. IgG anti-globulins in rheumatoid arthritis and other arthritides: Relationship with clinical features and other parameters
28. New developments in antinucleolar autoantibodies to nuclear antigens (ANA) in human diseases
29. Antibodies to histones in drug- induced and idiopathic lupus erythematosus
30. Diversity of antinuclear antibodies in progressive systemic sclerosis: Anticentromere antibody and its relationship to CREST syndrome
31. Autoantibody to a nuclear antigen in proliferating cells
32. Antibody to the mitotic spindle apparatus: Immunologic characteristics and cytological studies
33. Range of antinuclear antibodies in "healthy" individuals
34. Antinuclear antibody (ANA) and ANA profile tests in children with autoimmune disorders: A retrospective study
35. Diversity of antinuclear antibodies in progressive systemic sclerosis: Anticentromere antibody and its relationship to CREST syndrome
36. Profiles of antinuclear antibodies in systemic rheumatic diseases
37. Autoantibody to a nuclear antigen in proliferating cells
38. Antibody to the mitotic spindle apparatus: Immunologic characteristics and cytologic studies
39. Antinucleolar antibodies: Their frequency and diagnostic application
40. Laboratory Tests for antinuclear antibody (ANA) in rheumatic diseases
41. Serum-anti-γ-globulin and antinuclear factors in the aged
42. Prevalence of maternal Ro (SS-A) and La (SS-B) autoantibodies in relation to congenital heart block
43. Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies
44. HEp2 ANA EIA: A new fully automated assay for the screening of antinuclear antibodies
45. Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay
46. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus
47. The importance of tissue substrate in the SS-A/Ro antigen-antibody system
48. Small ribonucleo-proteins from eukaryotes: Structures and roles in RNA biogenesis
49. Antibodies to snRNPs in systemic lupus erythematosus
50. The structure of mammalian small nuclear ribonucleo-proteins. Identification of multiple protein components reactive with anti-(U1)ribonucleoprotein and anti-Sm autoantibodies
51. The use of Tween 20 in immunoblotting assays for the detection of autoantibodies in connective tissue diseases
52. Quantitation of anti-RNP and anti-Sm anti-bodies in MCTD and SLE patients by immunoblotting
53. The use of immunoblotting and immunoprecipitation of (U) small nuclear ribonucleoproteins in the analysis of sera of patients with mixed connective tissue disease and systemic lupus erythematosus. A cross-sectional, longitudinal study
54. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients
55. Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides
56. Autoantibody testing for connective tissue diseases. Comparison of immunodiffusion, immunoblot, and enzyme immunoassay
57. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic disease
58. Human anti-nuclear ribonucleoprotein antigen autoimmune sera contain a novel subset of autoantibodies that stabilizes the molecular interaction of U1RNP-C protein with the Sm core proteins
59. The C-termianl RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies
60. In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies
61. Mixed connective tissue disease
62. Mixed connective tissue disease: A subsequent evaluation of the original 25 patients
63. Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus
64. High frequency of antibody activity against ribosomal protein S10 in anti-Sm sera from patients with systemic lupus erythematosus
65. Delineation of the human systemic lupus erythematosus anti-smith antibody response using phage-display combinatorial libraries
66. Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren's syndrome
67. The clinical significance of autoantibody profiles in patients with systemic lupus erythematosus
68. Autoantibodies to the RoRNP particles
69. Isotype distribution of anti-Ro/SS-A and anti-La/SS-B antibodies in plasma and saliva of patients with Sjögren's syndrome
70. The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block
71. New insights into the pathogenesis of anti-Ro antibody associated congenital complete heart block
72. Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block
73. kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus
74. Selection and use of laboratory tests in the rheumatic diseases
75. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: Nuclear immunofluorescence patterns and ELISA reactivities
76. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis
77. Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies
78. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus
79. Autoantibodies in the diagnosis of systemic rheumatic diseases
80. Cell cycle-associated autoantibodies: Markers for autoimmunity and probes for molecular cell biology
81. Comparison of counter immunoelectrophoresis with immunoblotting for detection of anti-extractable nuclear antigen antibodies in systemic lupus erythematosus
82. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis
83. Anti-Jo-1 antibodies in polymyositis or dermatomyositis: Evaluation by ELISA using recombinant fusion protein Jo-1 as antigen
84. Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease
85. Biological markers in inflammatory rheumatic diseases
86. Autoantibodies in the diagnosis of systemic rheumatic diseases
87. Measurement of serum DNA-binding activity in systemic lupus erythematosus
88. A quantitative approach to the determination of antigen in immune complexes
89. Initiation of systemic autoimmunity and sequence specific anti-DNA autoantibodies
90. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus
91. Significance of persisting serologic abnormalities in SLE
92. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus
93. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus
94. The lupus erythematosus cell phenomenon: Comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera
95. IgM anti-histone H-3 antibody associated with undifferentiated rheumatic disease syndromes
96. Immunology of DNA. IV. Quantitative aspects of the Farr assay
97. Histone-containing immune complexes are to a large extent responsible for anti-ds-DNA reactivity in the Farr assay of active SLE patients
98. A Millipore filter assay for antibodies to native DNA in sera of patients with systemic lupus erythematosus
99. Antibodies to native DNA in systemic lupus erythematosus. A technique of rapid and quantitative determination
100. DNA antibody class, subclass, and complement fixation in systemic lupus erythematosus with and without nephritis
101. Anti-DNA antibodies in systemic lupus erythematosus
102. Antidouble stranded DNA antibody assays in systemic lupus erythematosus: Correlations of longitudinal antibody measurements
103. Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus
104. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity
105. The use of laboratory tests in the diagnosis of SLE
106. Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists
107. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology?
108. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease
109. Antineutrophil cytoplasmic autoantibodies: A review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences
110. Anticytoplasmic antibodies in Wegener's granulomatosis
111. Anticytoplasmic antibodies in Wegener's granulomatosis
112. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme
113. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters
114. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3
115. Antigen specificities and clinical distribution of ANCA in kidney diseases
116. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
117. ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects
118. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis
119. Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders
120. The Third International Workshop on antineutrophil cytoplasmic autoantibodies. Introduction
121. The clinical relevance of ANCA in vasculitis
122. Antineutrophil cytoplasm antibody (ANCA) associated vasculitis
123. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin
124. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener granulomatosis
125. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
126. Limited prognostic value of changes in anti-neutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis
127. ANCA and associated diseases: Immunodiagnostic and pathogenetic aspects
128. Antineutrophil cytoplasmic autoantibodies antigen specificity
129. Autoantibodies directed against lysozyme: A new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA)
130. Idiopathic rapidly progressive (crescentic) glomerulonephritis with myeloperoxidase antibodies - A new entity linked to female sex?
131. Anti-myeloperoxidase antibodies: Immunological characteristics and clinical associations
132. Association of autoantibodies to myeloperoxidase with different forms of vasculitis
133. Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis
134. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis
135. Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis
136. Antimyeloperoxidase antibodies and adverse reactions to clozapine
137. Laboratory findings in the vasculitides
138. ELISA is the superior method for detecting antineutrophil cytoplasmic antibodies in the diagnosis of systemic necrotising vasculitis
139. Clinical significance of ANCA in 98 patients
140. Antineutrophil cytoplasmic autoantibody testing in vasculitides
141. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients
142. Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance
143. Outcome of patients with anticardiolipin antibodies: A 10 year follow up of 52 patients
144. Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases
145. Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations
146. 2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome
147. 2-glycoprotein I antibodies in the antiphospholipid syndrome
148. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta(2)-glycoprotein I
149. Anti-cardiolipin antibodies in HIV infection are true antiphospholipids not associated with antiphospholipid syndrome
150. Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis
151. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
152. Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)
153. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome
154. Analysis of prothrombotic effects of two human monoclonal IgG antiophospholipid antibodies of apparently similar specificity
155. Use of the dilute Russell Viper Venom Time (dRVVT): Its importance and pitfalls
156. Immunology and clinical importance of antiphospholipid antibodies
157. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H)
158. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
159. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
160. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface
161. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases
162. Anti-beta 2-glycoprotein I antibodies: A useful marker for the antiphospholipid syndrome
163. Antibodies to beta2-glycoprotein I - A specific marker for the antiphospholipid syndrome
164. Reference calibrators for IgG antibodies to beta2-glycoprotein I: Preparation, properties and availability to investigators
165. Beta 2-glycoprotein I in thrombosis: Evidence for a role as a natural anticoagulant
166. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus
167. Anti-beta 2-glycoprotein I antibodies: A marker of antiphospholipid syndrome?
168. Anti-beta2-glycoprotein I, antiprothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome
169. 2-glycoprotein I ELISA: Methodology, determination of cut-off values in 434 healthy Caucasians and evaluation of monoclonal antibodies as possible international standards
170. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses
171. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: Importance of IgA isotype
172. 2-glycoprotein I IgA
173. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus
174. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and a beta2 glycoprotein-I is the most frequent isotype
175. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results
176. AMA-M2 do not directly produce ANCA indirect immunofluorescence patterns
177. Antimitochondrial antibody profiles in primary biliary cirrhosis distinguish at early stages between a benign and a progressive course: A prospective study on 200 patients followed for 10 years
178. Reactivity patterns of antiphospholipid antibodies and endothelial cells: Effect of antiendothelial antibodies on cell migration
179. Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behcet's disease
180. Behcet's disease sera containing antiendothelial cell antibodies promote adhesion of T lymphocytes to cultured human dermal microvascular endothelial cells
181. Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis
182. Antiendothelial cell antibodies: Useful markers of systemic sclerosis
183. Antiendothelial cell antibodies (AECA) in systemic lupus erythematosus (SLE)
184. Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies
185. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment
186. Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease
187. Anti-endothelial cell antibodies: Only for scientists or for clinicians too?
188. Pathogenic role of anti-endothelial cell antibodies in systemic vasculitis
189. Anti-endothelial cell antibodies in systemic sclerosis: Significant association with vascular involvement and alveolo-capillary impairment
190. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease
191. Antiendothelial cell antibodies in thromboangiitis obliterans
192. Mechanism of endothelial injury in vasculitis
193. Is antiendothelial cell antibody the murder weapon in systemic sclerosis?
194. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: Potential markers for disease activity